Delivery platforms will unlock personalized medicine
The guest argued that the ultimate value in biotechnology lies in building delivery platforms capable of reaching any cell in the body, mirroring tech delivery ecosystems like Apple's iPhone.
The argument
While current biotech focuses on single-drug assets for M&A, the guest argued that true personalization (bespoke therapies) requires robust delivery and manufacturing infrastructure to make the economics viable, similar to how smartphones enabled Spotify.
The thesis, stress-tested
✓ What validates it
- ✓Successful systemic CRISPR editing trials targeting organs outside the liver
- ✓Increased venture capital funding flowing into biotech platform delivery plays
▸ Risks discussed
- ▸High upfront capital expenditure required to build delivery infrastructure
- ▸Biological barriers to targeting non-liver organs like kidneys or the brain
Hear it yourself
"and safely. And so what we have essentially figured out a way to do is take that message, which is in the form of an, molecule called RNA. A lot of people are familiar with it from the COVID vaccines, but those are very small examples of what RNA could actually be utilized to do. And then we have found a way to send those messages into the body, into diseased areas where they can access the cells and essentially return the cells to a state of homeostasis, which either corrects the problem or, you know, in the case of cancer, removes the problem, any of those pieces."
07:15
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE